Chlorothiazide is a substrate for the human uptake transporters OAT1 and OAT3.
暂无分享,去创建一个
J. Zolnerciks | Z. Nagy | É. Molnár | Márton Jani | P. Krajcsi | Eva Molnár | Viktória Juhász | Erzsébet Beéry | Zoltán Nagy | Annamária Bui | Joseph Krisjanis Zolnerciks | Rémi Magnan | Peter Krajcsi | Viktória Juhász | M. Jani | E. Beéry | R. Magnan | Annamária Bui | Joseph K. Zolnerciks
[1] A. Greenberg. Original articleDiuretic Complications , 2000 .
[2] G. S. Gordon,et al. Studies with chlorothiazide tagged with radioactive carbon (C14) in human beings. , 1960, Archives of internal medicine.
[3] H. Saito,et al. Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. , 2000, The Journal of pharmacology and experimental therapeutics.
[4] H. Endou,et al. Urate transport via human PAH transporter hOAT1 and its gene structure. , 2003, Kidney international.
[5] Y. Kanai,et al. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. , 1999, American journal of physiology. Renal physiology.
[6] Y. Kanai,et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. , 2001, Molecular pharmacology.
[7] Maristela Lika Onozato,et al. Interactions of Human Organic Anion Transporters with Diuretics , 2004, Journal of Pharmacology and Experimental Therapeutics.
[8] A. Straughn,et al. Bioavailability of chlorothiazide tablets in humans. , 1979, Journal of pharmaceutical sciences.
[9] M. Leider. Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .
[10] F. Russel,et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. , 2008, Kidney international.
[11] G. Amidon,et al. Pharmacokinetics of probenecid following oral doses to human volunteers. , 1982, Journal of pharmaceutical sciences.
[12] F. Pea. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. , 2005, Contributions to nephrology.
[13] Conrad C. Huang,et al. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. , 2006, American journal of physiology. Renal physiology.
[14] M. Brandl,et al. Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[15] G. Burckhardt,et al. Human Organic Anion Transporter 3 (hOAT3) can Operate as an Exchanger and Mediate Secretory Urate Flux , 2003, Cellular Physiology and Biochemistry.
[16] Franciska Erdő,et al. ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions. , 2012, Drug metabolism and pharmacokinetics.
[17] E. Boerwinkle,et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout , 2009, Proceedings of the National Academy of Sciences.
[18] P. Welling,et al. Bioavailability of chlorothiazide from 50, 100, and 250 MG solution doses. , 1982, Biopharmaceutics & drug disposition.
[19] D. Goldfarb,et al. Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis. , 2007, The Journal of urology.
[20] D. Brater. Increase in diuretic effect of chlorothiazide by probenecid , 1978, Clinical pharmacology and therapeutics.